Xiao Xia, Lan Weixuan, Zhao Yaqin, Li Ruichao, Liu Yuan, Liu Juan, Wang Zhiqiang
College of Veterinary Medicine, Yangzhou University, Yangzhou, China.
Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou, China.
Front Microbiol. 2021 Jan 11;11:616685. doi: 10.3389/fmicb.2020.616685. eCollection 2020.
can invade and translocate through endothelial cells and result in vascular-system infection, which can cause severe economic losses in the poultry industry. Antibacterial therapy (especially florfenicol) plays an important part in controlling infection. To preserve the effect of florfenicol, pharmacokinetic/pharmacodynamic (PK/PD) modeling of florfenicol against three strains in duck was established. Then, the efficacy of the currently marketed dose, a rational dosage regimen for populations, and the PK/PD cutoff were predicted through Monte Carlo simulations (MCSs). The area under the concentration-time curve from 0 to 24 h/minimum inhibitory concentration (AUC /MIC) was the optimal PK/PD parameter. The PK/PD surrogate values of florfenicol against were similar using different organs as the PD target, but varied in different strains. For the florfenicol-sensitive strain 0825Y, when the AUC /MIC reached 117.54 and 108.19, florfenicol showed a bactericidal effect in the liver and lung, respectively. For the florfenicol-sensitive strain 0901J, the corresponding value was 78.39 and 54.30, respectively. For the florfenicol-resistant strain JY160110, florfenicol could attain a maximum effect of 1 - log reduction in bacteria in the liver and lung when the AUC /MIC reached 2.03 and 2.06, respectively. The PK/PD-based prediction for the population dose indicated a poor effect for the low end of the currently marketed dose (40 mg/kg body weight per day), but a robust effect for the high end of the currently marketed dose (60 mg/kg body weight per day) with a target attainment rate of 92.79% and 81.44% against in mainland China and worldwide, respectively. The recommended dose optimized by MCSs was 52 mg/kg body weight in mainland China. The PK/PD cutoff of florfenicol against at the low end and high end of the current daily dose (40 and 60 mg/kg body weight) and predicted daily dose in mainland China (52 mg/kg body weight) was 0.25, 4, and 0.5 μg/ml, respectively. These results suggested that more than one strain should be involved for PK/PD modeling and contributed to rational use of florfenicol in populations. We also provided fundamental data for determination of florfenicol breakpoints in poultry.
可侵入并通过内皮细胞转移,导致血管系统感染,这会给家禽业造成严重经济损失。抗菌治疗(尤其是氟苯尼考)在控制感染方面发挥着重要作用。为了保持氟苯尼考的疗效,建立了氟苯尼考对鸭的三种菌株的药代动力学/药效学(PK/PD)模型。然后,通过蒙特卡洛模拟(MCS)预测了当前市售剂量的疗效、针对群体的合理给药方案以及PK/PD临界值。0至24小时浓度-时间曲线下面积/最低抑菌浓度(AUC/MIC)是最佳的PK/PD参数。以不同器官作为药效学靶点时,氟苯尼考对[具体菌株信息缺失]的PK/PD替代值相似,但在不同菌株中有所不同。对于氟苯尼考敏感菌株0825Y,当AUC/MIC分别达到117.54和108.19时,氟苯尼考在肝脏和肺中分别显示出杀菌作用。对于氟苯尼考敏感菌株0901J,相应的值分别为78.39和54.30。对于氟苯尼考耐药菌株JY160110,当AUC/MIC分别达到2.03和2.06时,氟苯尼考在肝脏和肺中对细菌的最大杀菌效果可达1个对数级降低。基于PK/PD的群体剂量预测表明,当前市售剂量的低端(每天40毫克/千克体重)效果不佳,但高端(每天60毫克/千克体重)效果显著,在中国内地和全球针对[具体菌株信息缺失]的达标率分别为92.79%和81.44%。通过MCS优化的推荐剂量在中国内地为52毫克/千克体重。当前每日剂量(40和60毫克/千克体重)以及中国内地预测每日剂量(52毫克/千克体重)下氟苯尼考对[具体菌株信息缺失]的PK/PD临界值分别为0.25、4和0.5微克/毫升。这些结果表明,PK/PD建模应涉及多种菌株,有助于氟苯尼考在群体中的合理使用。我们还为确定家禽中氟苯尼考的断点提供了基础数据。